Dogs with leishmaniosis: how are we managing proteinuria in daily practice? A Portuguese questionnaire-based study

Table 3 First-choice drugs and combined protocols chosen by respondents for the treatment of proteinuria in the clinical scenarios of CanL stages IIb, III and III

First-choice drugs and combined protocols	LeishVet classification
First-choice drugs and combined protocols	Stage IIb (n = 14)	Stage III (n = 54)	Stage IV (n = 76)
a. First-choice drugs^a
ACEI	14 (100%)	46 (85.2%)	60 (78.9%)
ARB	0%	5 (9.3%)	10 (13.2%)
CCB	0%	2 (3.7%)	4 (5.3%)
Antithrombotic therapy	0%	1 (1.9%)	2 (2.6%)
b. Single-drug and combined protocols^b
ACEI	9 (64.3%)	22 (40.7%)	35 (46.1%)
ACEI + NA	4 (28.7%)	7 (13.0%)	0%
ACEI + aldosterone receptor blockers	0%	1 (1.9%)	1 (1.3%)
ACEI + antithrombotic therapy	0%	6 (11.1%)	11 (14.5%)
ACEI + ARB	1 (7.1%)	4 (7.4%)	9 (11.8%)
ACEI + CCB	0%	2 (3.7%)	3 (3.9%)
ACEI + ARB + antithrombotic therapy	0%	0%	3 (3.9%)
ACEI + CCB + aldosterone receptor blockers	0%	0%	1 (1.3%)
ACEI + other	0%	5 (9.3%)	2 (2.6%)
SUM (ACEI with other compounds)	1 (7.1%)	18 (33.3%)	30 (39.5%)
ARB	0%	4 (7.4%)	6 (7.9%)
ARB + antithrombotic therapy	0%	1 (1.9%)	1 (1.3%)
CCB	0%	0%	4 (5.3%)
CCB + NA	0%	2 (3.7%)	0%
SUM (protocols without ACEI)	0%	7 (12.9%)	11 (14.5%)

ACEI angiotensin converting enzyme inhibitors angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CCB Calcium channel blockers, NA no answer/not detailed
^aOnly one option available
^bOne or more options available

ISSN: 1756-3305